Xendee Releases New Features for Effectively Designing Sustainable Communities, Large Facilities, and Utility-Scale Microgrids

Xendee’s optimization software even takes into account cable length, losses through transferring energy, and the most efficient ways to generate and distribute energy from multiple energy sources at all hours of the day.

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Excision BioTherapeutics announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1).